Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1700 CAD | -8.11% | -5.56% | -19.05% |
Dec. 31 | Innocan Pharma Closes Private Placement for $635,444 | MT |
Dec. 30 | InnoCan Pharma Corporation announced that it has received CAD 0.635445 million in funding | CI |
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Profitability | ||||||
Return on Assets | -115.71 | -85.4 | -55.3 | -40.06 | -34.16 | |
Return on Total Capital | -232.71 | 283.41 | -171.78 | -51.29 | -44.52 | |
Return On Equity % | -433.12 | 907.29 | -373.46 | -51.05 | -80.07 | |
Return on Common Equity | -433.12 | 907.29 | -368.83 | -48.73 | -89.55 | |
Margin Analysis | ||||||
Gross Profit Margin % | - | 37.5 | 61.73 | 82.34 | 87.71 | |
SG&A Margin | - | 37.3K | 3.16K | 267.57 | 102.4 | |
EBITDA Margin % | - | -58.56K | -3.79K | -243.49 | -27.6 | |
EBITA Margin % | - | -59.06K | -3.82K | -244.86 | -27.85 | |
EBIT Margin % | - | -59.06K | -3.82K | -244.86 | -27.85 | |
Income From Continuing Operations Margin % | - | -124K | -5.15K | -151.97 | -31.1 | |
Net Income Margin % | - | -124K | -5.13K | -147.09 | -34.41 | |
Net Avail. For Common Margin % | - | -124K | -5.13K | -147.09 | -34.41 | |
Normalized Net Income Margin | - | -77.76K | -3.2K | -90.07 | -21.77 | |
Levered Free Cash Flow Margin | - | 37.44K | -3.78K | -244.06 | -5.27 | |
Unlevered Free Cash Flow Margin | - | 37.44K | -3.78K | -244.01 | -5.27 | |
Asset Turnover | ||||||
Asset Turnover | - | 0 | 0.02 | 0.26 | 1.96 | |
Fixed Assets Turnover | - | 0.11 | 3.56 | 33.67 | 116.73 | |
Receivables Turnover (Average Receivables) | - | - | - | - | 87.83 | |
Inventory Turnover (Average Inventory) | - | - | 0.16 | 0.55 | 1.17 | |
Short Term Liquidity | ||||||
Current Ratio | 2.2 | 0.54 | 3.51 | 9.41 | 2.68 | |
Quick Ratio | 1.79 | 0.44 | 3.15 | 7.1 | 1.8 | |
Operating Cash Flow to Current Liabilities | -2.4 | -0.46 | -1.86 | -8.3 | -1.54 | |
Days Sales Outstanding (Average Receivables) | - | - | - | - | 4.16 | |
Days Outstanding Inventory (Average Inventory) | - | - | 2.29K | 662.57 | 312.83 | |
Average Days Payable Outstanding | - | - | 682.9 | 25.17 | 16.46 | |
Cash Conversion Cycle (Average Days) | - | - | - | - | 300.52 | |
Long Term Solvency | ||||||
Total Debt/Equity | 5.1 | -1.05 | 0.01 | 0.55 | 0.75 | |
Total Debt / Total Capital | 4.85 | -1.06 | 0.01 | 0.54 | 0.75 | |
LT Debt/Equity | 2.69 | -0.03 | - | 0.32 | 0.25 | |
Long-Term Debt / Total Capital | 2.56 | -0.03 | - | 0.32 | 0.25 | |
Total Liabilities / Total Assets | 45.27 | 183.23 | 28.34 | 10.77 | 36.8 | |
EBIT / Interest Expense | -75.02 | - | -575.38 | -3.13K | - | |
EBITDA / Interest Expense | -74.45 | - | -572.08 | -3.12K | - | |
(EBITDA - Capex) / Interest Expense | -74.68 | - | -575.23 | -3.13K | - | |
Total Debt / EBITDA | -0.02 | -0.01 | -0 | -0.01 | -0.01 | |
Net Debt / EBITDA | 0.64 | 0.49 | 1.49 | 0.79 | 1.02 | |
Total Debt / (EBITDA - Capex) | -0.02 | -0.01 | -0 | -0.01 | -0.01 | |
Net Debt / (EBITDA - Capex) | 0.64 | 0.49 | 1.48 | 0.79 | 1.01 | |
Growth Over Prior Year | ||||||
Total Revenues, 1 Yr. Growth % | - | - | 2.35K | 1.21K | 433.68 | |
Gross Profit, 1 Yr. Growth % | - | - | 3.93K | 1.64K | 468.49 | |
EBITDA, 1 Yr. Growth % | - | 57.32 | 58.74 | -16.22 | -39.5 | |
EBITA, 1 Yr. Growth % | 50.14 | 57.45 | 58.31 | -16.23 | -39.31 | |
EBIT, 1 Yr. Growth % | 50.14 | 57.45 | 58.31 | -16.23 | -39.31 | |
Earnings From Cont. Operations, 1 Yr. Growth % | 63.21 | 198.44 | 1.39 | -61.46 | 9.23 | |
Net Income, 1 Yr. Growth % | 63.21 | 198.44 | 0.94 | -62.54 | 24.87 | |
Normalized Net Income, 1 Yr. Growth % | 63.21 | 198.44 | 0.68 | -63.2 | 28.99 | |
Diluted EPS Before Extra, 1 Yr. Growth % | 14.25 | 122.23 | -27.16 | -66.21 | 20.95 | |
Accounts Receivable, 1 Yr. Growth % | - | - | - | - | 301.61 | |
Inventory, 1 Yr. Growth % | - | - | 18.6 | 121.76 | 54.46 | |
Net Property, Plant and Equip., 1 Yr. Growth % | 3.07K | -41.05 | -3.57 | 81.48 | 38.78 | |
Total Assets, 1 Yr. Growth % | 291.21 | 67.85 | 190.15 | -44.52 | -0.52 | |
Tangible Book Value, 1 Yr. Growth % | 1.01K | -355.27 | -351.04 | -29.39 | -35.83 | |
Common Equity, 1 Yr. Growth % | 1.01K | -355.27 | -351.04 | -29.39 | -35.83 | |
Cash From Operations, 1 Yr. Growth % | 74.23 | 35.8 | 79.79 | -8.48 | -35.65 | |
Capital Expenditures, 1 Yr. Growth % | 75 | - | - | -36.59 | 76.92 | |
Levered Free Cash Flow, 1 Yr. Growth % | - | -409.51 | -284.93 | -15.68 | -88.47 | |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | -417.72 | -284.5 | -15.61 | -88.47 | |
Compound Annual Growth Rate Over Two Years | ||||||
Total Revenues, 2 Yr. CAGR % | - | - | - | 1.69K | 734.74 | |
Gross Profit, 2 Yr. CAGR % | - | - | - | 2.55K | 894.95 | |
EBITDA, 2 Yr. CAGR % | - | - | 58.03 | 15.33 | -28.8 | |
EBITA, 2 Yr. CAGR % | - | 53.75 | 57.88 | 15.16 | -28.7 | |
EBIT, 2 Yr. CAGR % | - | 53.75 | 57.88 | 15.16 | -28.7 | |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | 120.7 | 73.95 | -37.49 | -35.12 | |
Net Income, 2 Yr. CAGR % | - | 120.7 | 73.57 | -38.5 | -31.6 | |
Normalized Net Income, 2 Yr. CAGR % | - | 120.7 | 73.34 | -39.13 | -31.1 | |
Diluted EPS Before Extra, 2 Yr. CAGR % | - | 59.34 | 27.23 | -50.39 | -36.07 | |
Accounts Receivable, 2 Yr. CAGR % | - | - | - | 456.78 | - | |
Inventory, 2 Yr. CAGR % | - | - | - | 62.18 | 85.08 | |
Net Property, Plant and Equip., 2 Yr. CAGR % | - | 332.05 | -24.61 | 32.29 | 58.7 | |
Total Assets, 2 Yr. CAGR % | - | 156.26 | 120.69 | 26.87 | -25.71 | |
Tangible Book Value, 2 Yr. CAGR % | - | 432.93 | 153.15 | 33.14 | -32.69 | |
Common Equity, 2 Yr. CAGR % | - | 432.93 | 153.15 | 33.14 | -32.69 | |
Cash From Operations, 2 Yr. CAGR % | - | 53.82 | 56.26 | 28.28 | -23.26 | |
Capital Expenditures, 2 Yr. CAGR % | - | - | 113.44 | - | 5.92 | |
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | 176.69 | 24.86 | -68.83 | |
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | 180.19 | 24.77 | -68.81 | |
Compound Annual Growth Rate Over Three Years | ||||||
Total Revenues, 3 Yr. CAGR % | - | - | - | - | 1.1K | |
Gross Profit, 3 Yr. CAGR % | - | - | - | - | 1.49K | |
EBITDA, 3 Yr. CAGR % | - | - | - | 27.9 | -6.99 | |
EBITA, 3 Yr. CAGR % | - | - | 55.25 | 27.81 | -6.98 | |
EBIT, 3 Yr. CAGR % | - | - | 55.25 | 27.81 | -6.98 | |
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | 70.29 | 5.26 | -24.71 | |
Net Income, 3 Yr. CAGR % | - | - | 70.04 | 4.12 | -22.13 | |
Normalized Net Income, 3 Yr. CAGR % | - | - | 69.89 | 3.41 | -21.81 | |
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | 22.74 | -18.22 | -33.23 | |
Accounts Receivable, 3 Yr. CAGR % | - | - | - | - | 399.33 | |
Inventory, 3 Yr. CAGR % | - | - | - | - | 59.57 | |
Net Property, Plant and Equip., 3 Yr. CAGR % | - | - | 162.07 | 1.04 | 34.42 | |
Total Assets, 3 Yr. CAGR % | - | - | 167.09 | 39.28 | 16.99 | |
Tangible Book Value, 3 Yr. CAGR % | - | - | 314.66 | 65.4 | 4.39 | |
Common Equity, 3 Yr. CAGR % | - | - | 314.66 | 65.4 | 4.39 | |
Cash From Operations, 3 Yr. CAGR % | - | - | 62.03 | 30.74 | 1.92 | |
Capital Expenditures, 3 Yr. CAGR % | - | - | 99.77 | 42.42 | - | |
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | - | 86.19 | -43.57 | |
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | - | 87.81 | -43.59 | |
Compound Annual Growth Rate Over Five Years | ||||||
EBITA, 5 Yr. CAGR % | - | - | - | - | 13.73 | |
EBIT, 5 Yr. CAGR % | - | - | - | - | 13.73 | |
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | - | - | 15.76 | |
Net Income, 5 Yr. CAGR % | - | - | - | - | 18.13 | |
Normalized Net Income, 5 Yr. CAGR % | - | - | - | - | 18.41 | |
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | - | - | -5.45 | |
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | - | - | 114.43 | |
Total Assets, 5 Yr. CAGR % | - | - | - | - | 60.09 | |
Tangible Book Value, 5 Yr. CAGR % | - | - | - | - | 100.38 | |
Common Equity, 5 Yr. CAGR % | - | - | - | - | 100.38 | |
Cash From Operations, 5 Yr. CAGR % | - | - | - | - | 20.16 | |
Capital Expenditures, 5 Yr. CAGR % | - | - | - | - | 54.99 |
- Stock Market
- Equities
- INNO Stock
- Financials InnoCan Pharma Corporation
- Financial Ratios